Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
TEL AVIV, Israel, March 01, 2016 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced corporate presentations at the upcoming 28th Annual ROTH Conference and the Barclays Global Healthcare Conference.
| 28th Annual ROTH Conference | |
| Date: | Monday, March 14 |
| Time: | 1:00pm Pacific Time |
| Location: | Ritz Carlton, Laguna Niguel, California |
| Presenter: | David Baker, Chief Commercial Officer |
| Barclays Global Healthcare Conference | |
| Date: | Thursday, March 17 |
| Time: | 10:45am Eastern Time |
| Location: | Loews Miami Beach Hotel, Miami, Florida |
| Presenter: | Dr. Yaron Daniely, President & Chief Executive Officer |
| Webcast: | https://cc.talkpoint.com/barc002/031516a_ae/?entity=72_U2Q8T5Q |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 [email protected] Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 [email protected] Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 [email protected]
